Unitech Pharmaceuticals, Inc.

Other

Geneblue Corporation

Jiajiu Shaw

An-Rong Lee

Wen-Hsin Huang

Ming-Kuan Hu

Chia-Mu Shao

A magnetic dart board that includes embedded conductor coils beneath scoring areas. When a dart with a magnetic head strikes a scoring area of the dart board a current is induced in the underlying conductor coil. The induced current provides an electrical signal that is transmitted to an automatic scoring system that calculates and displays scores. The dart board is made from a plurality of layers including a top layer, an insulating layer, a sensing layer and a body layer. The multi-layered dart board is flexible and can be rolled up for storage, shipping and transportation.

Flexible magnetic dart board with the capability of automatic scoring

A series of isoxazole derivatives and methods of suppressing, inhibiting, or preventing disorders mediated by nitric oxide (NO) and/or proinflammatory cytokines, such as TNF-&#x3b1; (tumor necrosis factor alpha), IL-1 (interlukin-1), and IL-6, are described.

Isoxazole derivatives and methods of treating nitric oxide mediated diseases

A series of dynamic platinum compounds for cancer treatment are described. The compounds may become active and inactive reversibly.

Dynamic anticancer platinum compounds

Methods of treating cancer employing isoxazole derivatives are described. Compounds and methods of using these compounds for isolating and/or detecting binding proteins, which may be indicative of a disease, are also described.

Methods, compounds, and diagnostics for cancer treatment

This invention relates to a controlled release delivery system of solid dosage form with a plurality of controls on the release of the active ingredient or ingredients.

Controlled release delivery system of solid dosage form

Novel leflunomide analogs were synthesized and evaluated in-vivo. Based on the in-vivo studies, these analogs are surprisingly effective for treating rheumatoid arthritis.

Leflunomide analogs for treating rheumatoid arthritis

The synthesis and the use of a series of carboplatin analogs is disclosed. These carboplatin analogs may be represented by cis-Pt(II)L L , wherein each of L and L , independently, is the carboxylate of phosphatidylserine, an &agr;-amino acid, a &bgr;-amino acid, or a derivative thereof, wherein each ligand is bidentate with &mdash;NH and &mdash;COO as the binding sites. The complexes can be used in the treatment of cancer.

Carboplatin analogs for cancer treatment

The synthesis and the use of a series of carboplatin analogs is disclosed. These carboplatin analogs may be represented by cis-Pt(II)L L , wherein each of L and L , independently, is the carboxylate of phosphatidylserine, an &agr;-amino acid, &bgr;-amino acid, or a derivative thereof, wherein each ligand is bidentate with &mdash;NH and &mdash;COO as the binding sites. The complexes can be used in the treatment of cancer.

A novel pharmaceutical composition, comprising cisplatin and folic acid is disclosed. The preparation of this pharmaceutical composition is also disclosed. The composition may be used to treat cancers and Acquired Immune Deficiency Syndrome (AIDS).

Cisplatin and folic acid administered to treat breast cancer

A series of tacrine derivatives has be synthesized and disclosed. These tacrine derivatives were claimed to be new and be useful for the treatment of Alzheimer's disease alone or in combination with other drugs for Alzheimer's disease. These tacrine derivatives may be formulated into suitable pharmaceutical dosage forms for the treatment of Alzheimer's disease.

Tacrine derivatives for treating Alzheimer's disease

This invention comprises the synthesis and the use of a new class of cisplatin analogs. These analogs are complexes formed between tetrachloroplatinum (II) and triethylenetetraamine or its derivatives. The stoichiometric ratio between cisplatin and triethylenetetraamine or its derivatives is between 0.4:1 to 0.5:0.8. The complexes are to be used in cancer treatment; they may also be used to treat AIDS patients.

Dinuclear platinum complexes as cisplatin analogs for cancer treatment

A pharmaceutical composition, comprising cisplatin, a special carrier and, optionally, customary pharmaceutical excipients, is disclosed. The preparation of this pharmaceutical composition is also disclosed. The composition may be used to treat cancer and Acquired Immune Deficiency Syndrome (AIDS).

Pharmaceutical composition comprised of cisplatin, and processes for

This invention comprises the synthesis and the use of two cisplatin analogs �Pt(NH.sub.3).sub.2 Cl(C.sub.10 H.sub.13 N.sub.5 O.sub.5)!Cl and �Pt(NH.sub.3).sub.2 (C.sub.10 H.sub.13 N.sub.5 O.sub.5).sub.2 !Cl.sub.2, whereby (C.sub.10 H.sub.13 N.sub.5 O.sub.5) is guanosine. The stoichiometric ratio between cisplatin and guanosine may be 1:1 or 1:2. The complexes are to be used in cancer treatment, they may also be used to treat AIDS patients.

Growing community of inventors

Ann Arbor, MI, United States of America

Jiajiu Shaw